top of page

Ki-Taek Lim, Ph.D.

CLICK:  Biographical Sketch



Office: Bldg 307 Rm 205

Phone: +82-33-250-6491


advancing logo.PNG


  • Stem cell-reactor automated system

  • 3D bioprinted drug delivery hydrogel patches

  • Cell therapeutics based on tissue engineering and regenerative medicine

  • Cancer therapy based on Bio/Nano-technology applications

  • NK cell-derived exosome cancer immunotherapy 

  • A simple test kit for the detection of nanoparticles

  • 4D printing for science robotics


  • Prof. Lim completed his undergraduate degrees in Biosystems Engineering at Konkuk University and an MA in Biomechatronics from Sungkyunkwan University. Ki-Taek continued his doctoral studies in Biosystems Engineering at Seoul National University under the joint supervision of Prof. Jong Hoon Chung. He held a postdoctoral appointment at Dental Research Institute, Seoul National University where he developed high-throughput automated culture platforms via a bioreactor process engineering for enhanced tissue regeneration from stem cells in Prof. Pill-Hoon Choung’s laboratory, plus, he developed nanoparticles as tools to control stem cells in Prof. Jin-Woo Kim’s Bio/Nano-Technology Group, Institute for Nanoscience and Engineering, University of Arkansas, Fayetteville. Ki-Taek joined KNU as an Assistant Professor of Biosystems Engineering in Feb. 2015, with getting along with an Adjunct Professor and a Visiting Scholar at SNU (Seoul National University)



  • Broadly, research in the Lim group integrates new bioreactor process, optical, and bio/nano-technology tools for application in biology and agricultural engineering. We pioneer the bio-convergence system in biosystems engineering approaches, aiming to enable multi-parametric studies with the power to reveal the workings of natural and engineered biological systems.


Research Areas: 

  • Bioreactor Engineering/Automated Bioreactor System: Engineering Parameters in Bioreactor’s Design

  • Automation and -Robotics for Biological Engineering

  • Tissue Engineering and Regenerative Medicine

  • Bioceramics for Bone Tissue Engineering

  • Stem Cell Culture Technologies & Convergence Engineering based on 3D Printing & Micro-Nano Platforms 

  • Pathogen Detection Systems using fully automated-on site microbiological testing productions.




Biomechagen is pioneering the development of a new class of specific therapeutic nanoengineering healingforms. Our new technology platform is based on the discovery of exosome functions s to block the immune processes causing immune-mediated diseases. Biomechagen is a privately held biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Biomechagen's initial portfolio is comprised of long-acting antifungal product candidates, exosome-skincare and its healing nanohydrogel patches for the treatment of serious fungal infections. In addition, Biomechagen has developed a proprietary immunotherapy platform, HydrogelBG, designed to create antifungals, antibacterials and antivirals that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease.


Biomechagenis headquartered in Chuncheon, South Korea.

Synergistic Platforms of Next-Generation

bottom of page